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Introduction
Phagocytic cells, including neutrophils as well as macrophages, generate nitric oxide (NO) via an NO synthase that is inducible by immunological stimuli such as endotoxin (LPS) and various cytokines (Hibbs et al., 1988; Marletta et al., 1988; McCall et al., 1989; Schmidt et al., 1989; Stuehr & Nathan, 1989; Wright et al., 1989; Billiar et al., 1990; Curran et al., 1990) . Generation of NO by macrophages has been showed to kill tumour cells due to the inactivation of ironsulphur centres of mitochondrial enzymes (Drapier & Hibbs, 1986; Hibbs et al., 1987; . The broader role of NO in the inflammatory response is not well established, although the reactivity of NO or its potential conversion product, peroxynitrite anion, with sulphydryl groups indicates the possibility of cellular biochemical targets whose alteration would put tissue at risk of injury.
Recently, it has been demonstrated that IgG immune complex-initiated injury of rat lung is greatly attenuated by the presence of the L-arginine analogue, NG-monomethyl-Larginine (L-NMMA) (Mulligan et al., 1991) . The protective effects of L-NMMA were not associated with a reduced influx of neutrophils into lungs, suggesting that toxic metabolites of L-arginine may be responsible for the inflammatory injury, which is known to depend upon the recruitment and participation of neutrophils (Johnson & Ward, 1979) . Since N-iminoethyl-L-ornithine (L-NIO) has recently been described as a highly potent inhibitor of phagocytic cell NO synthase (McCall et al., 1991 ), this compound was tested for its ability to protect against immune complex-induced vascular injury in rats. In addition, the effects of L-NIO were compared with those of other L-arginine analogues, namely, L-NMMA, NGnitro-L-arginine (L-NNA) and its methyl ester (L-NAME).
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Methods

Models of immune complex-induced alveolitis and dermal vasculitis
With adult male (300 g) specific pathogen-free Long-Evans rats (Charles River Breeding Laboratories), immune complex reactions were induced in lung and skin by the intratracheal (2.5 mg of antibody in 300,l) or intradermal (0. (Mulligan et al., 1991 
Results
Protective effects of L-arginine analogues in dermal vascular injury
Immune complex deposition was induced by the intra-dermal injection of anti-BSA and the intravenous injection of BSA. The resulting vascular injury was measured 4 h later by leakage of ['25I]-albumen into skin sites. In the negative controls (omission of intravenously injected BSA) and positive controls, the permeability values were 0.07 ± 0.01 and 0.81 ± 0.03, respectively. When used, the L-arginine analogues were mixed with the anti-BSA preparations immediately prior to intradermal injection. Concentrations of the analogues employed were: 0.01, 0.1, 0.5, 1.0 and 5.0mm. The data in Figure 1 show the comparative abilities of the four analogues of L-arginine to reduce immune complex-induced vascular injury, as measured by changes in vascular permeability. The most effective compound was L-NIO, which caused a marked reduction in the increase in vascular permeability. L-NIO had an estimated IC50 of 65 JM. At 1.0 mM, L-NMMA reduced the permeability change by 32%, but this was not further reduced with 5 mM L-NMMA. L-NNA and L-NAME were much less potent; at 5 mM, the protective effects were only 19% and 16%, respectively. Thus, the rank order of protec-0.9 tive effects for these L-arginine analogues in immune com-
Ability of L-arginine to reverse protective effects of L-NIO In the same model of immune complex-induced dermal vascular damage, the presence of 1.0 mM L-NIO in the anti-BSA preparation resulted in a fall in the permeability index from the positive control (absence of L-NIO), from 0.81 ± 0.03 to 0.46 ± 0.02, a 47% reduction (P <0.001) in the permeability index. As L-arginine was added in increasing concentrations to anti-BSA preparations which contained 1.0 mM L-NIO, the reductions (reversals) in vascular permeability reflecting the protective effects of L-NIO were correspondingly reversed: with 0.1, 0.5, 1.0, 5.0 and 10mM L-arginine, the permeability values were: 0.55 ± 0.03 (35% reduction, P = 0.002); 0.66 ± 0.04 (20% reduction, P = 0.049); 0.74 ± 0.02 (9% reduction, P = NS); 0.81 ± 0.02 (0% reduction, P = NS), and 0.93 ± 0.02 (16% increase in permeability compared to the positive control, P = NS), respectively. The presence of 1.0 mM D-arginine with 1.0 mM L-NIO did not reverse the protective effects of the latter (data not shown).
Protective effects of L-NIO in immune complex induceddermal vascular injury: effects on tissue MPO content These experiments were carried out with positive and negative (omission of intravenously injected BSA) controls and extraction of skin sites at 4 h for MPO following deposition of immune complexes. In a comparison series of skin sites injected with anti-BSA containing 1.0 mM L-NIO alone or in combination with 1 mM D-arginine, or with 0.1, 0.5, 1.0, 5.0 or 10 mM L-arginine, a protocol similar to that described in (measured by leakage of ['251l-albumen) When lungs from animals undergoing immune complex deposition were compared for MPO content to those lungs in which anti-BSA also contained L-NIO or L-NMMA, no difference was found in the lung content of MPO (data not shown), confirming the pattern found for the protective effects of analogues of L-arginine in the skin (described above).
Discussion
The ability of L-arginine analogues to reduce evidence of IgG immune complex-induced dermal vascular injury in rats reveals the rank order of potency: L-NIO> L-NMMA> L-NNA = L-NAME, which is in remarkable agreement with the in vitro effects of these compounds on their ability to block NO synthase in rat peritoneal neutrophils or in J774 cells, whether measured by interference with platelet aggregation or by direct measurement of NO formation in cytosolic fractions of cells (McCall et al., 1991) . The estimated IC50 value (65 I.M) for the in vivo protective effects of L-NIO in skin is much higher than the value obtained in vitro (0.8 gM), but this is readily explained by the fact that the total volume of intradermally injected material is 50 1d, which becomes rapidly diluted as the permeability changes begin to occur in the developing acute inflammatory reaction. Since the minimal volume increase in the positive control sites is nearly 16 fold (to 800 pl) above the negative control value and the outflow, chiefly through efferent lymphatic channels, has not been measured, the effective local in vivo concentration cannot be accurately computed but would probably be reduced many fold below the initial concentration, perhaps to <31tM. A key factor in the efficacy of L-NIO when compared to the other analogues of L-arginine appears to be the more rapid onset in its inhibitory effects when added to the phagocytic cells (10 min versus 20-60 min) and the irreversible effect of L-NIO as compared to the other analogues (McCall et al., 1991) .
These data indicate that L-arginine analogues such as L-NIO may be useful in preventing tissue damage which is generated by toxic products of activated neutrophils (and macrophages). In the rat dermal and lung models of immune complex-induced vascular injury, neutrophils have long been shown to be key participants in the events leading to injury (Johnson & Ward, 1979; Warren et al., 1990) . The protective effects of antioxidants such as superoxide dismutase (SOD) and catalase have led to the suggestion that toxic metabolites of oxygen may be key initiators of injury (Johnson & Ward, 1981) . The protective effects of SOD are complicated by the fact that this compound has time-limited protective effects (2 h) in the immune complex models of injury (Johnson & Ward, 1981) , which may be related to the generation of 02-dependent chemotactic lipids (Von Zabern et al., 1987; Vogt et al., 1989) . The recent finding that L-NMMA has significant protective effects in immune complex-induced injury in rat lung and skin (Mulligan et al., 1991) has caused a re-evaluation of the pathways leading to injury and has emphasized that L-arginine, or presumably its metabolic products, are injurious, perhaps through the generation of peroxynitrite anion or the hydroxyl radical (Beckman et al., 1990) . The most remarkable finding in the earlier study (Mulligan et al., 1991) and in the current one is that the protective effects are not associated with a reduced tissue accumulation of neutrophils, implying that the protective effects of L-NIO and L-NMMA are not attributable to an interference with neutrophil emigration from the vasculature. The current studies indicate that compounds capable of blocking NO formation may have significant protective effects against injury in a variety of human inflammatory diseases.
